NextRNA
PrivateLast Round
Series A
Mar 1, 2022
Total Funding Raised
$56.1M
Company Overview
NextRNA is a biotechnology company focused on developing targeted therapeutics that identify and modulate non-coding ribonucleic acids (ncRNAs) to disrupt disease-related interactions and aid in the treatment of various diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NextRNA Comps
Public and private peers based on sector, stage, and business model.
NextRNA Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 1, 2022 | ||||
| Seed | Mar 1, 2022 |
Key People
Founding team and executive leadership
NextRNA Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | Seed, Series A |
| Circle Squared Alternative Investments | Series A |
| Evans Capital | Seed, Series A |
| Rivas Capital | Seed, Series A |
| Willett Advisors | Seed, Series A |
| Cobro Ventures | Seed, Series A |
| LightChain Capital | Seed, Series A |
NextRNA Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NextRNA's valuation, stock price, and market status.
